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Abstract
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Aims: The goal of the STAR (STrengthening Altitude Research) initiative was to produce a uniform set of key
elements for research and reporting in clinical high-altitude (HA) medicine. The STAR initiative was inspired by
research on treatment of cardiac arrest, in which the establishment of the Utstein Style, a uniform data reporting
protocol, substantially contributed to improving data reporting and subsequently the quality of scientific evidence.
Materials and Methods: The STAR core group used the Delphi method, in which a group of experts reaches a
consensus over multiple rounds using a formal method. We selected experts in the field of clinical HA medicine
based on their scientific credentials and identified an initial set of parameters for evaluation by the experts.
Results: Of 51 experts in HA research who were identified initially, 21 experts completed both rounds. The
experts identified 42 key parameters in 5 categories (setting, individual factors, acute mountain sickness and HA
cerebral edema, HA pulmonary edema, and treatment) that were considered essential for research and reporting
in clinical HA research. An additional 47 supplemental parameters were identified that should be reported
depending on the nature of the research.
Conclusions: The STAR initiative, using the Delphi method, identified a set of key parameters essential for
research and reporting in clinical HA medicine.
Keywords: clinical research; Delphi method; guidelines; high altitude; Utstein style
Introduction
H igh-altitude (HA) research is of international in-terest for clinicians and translational scientists. HA re-
search has broad clinical implications due to the nature of
hypobaric hypoxic exposure and its physiological conse-
quences. Since the inception of HA field research by teams of
clinicians, such as the Silver Hut Expedition in 1960–1961
(Michel and Milledge, 1963; Milledge, 1963, 2010), there
has been a steady increase in the number of clinical and basic
science research studies related to HA medicine (Brugger
et al., 2017). Despite previous efforts to standardize clinical
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parameters of HA-related illnesses, such as the Lake Louise
consensus acute mountain sickness (AMS) score (Roach
et al., 1991), there remains a lack of uniformity in defining
and reporting basic parameters in clinical HA research. Due
to the lack of uniformity, studies are heterogeneous. Many
studies incompletely report key data. This makes it difficult to
reproduce or compare studies and to perform reliable meta-
analyses. To strengthen clinical HA research, it is necessary
to formulate a common language and standard definitions.
The STAR initiative was inspired by research on treatment
of cardiac arrest, in which the establishment of the Utstein
Style, a uniform data reporting protocol, substantially con-
tributed to improving data reporting and subsequently the
quality of scientific evidence (Cummins et al., 1991). The Ut-
stein Style was developed in 1991 by a group of experts. It was
the first consensus-based guideline for uniform data reporting.
The expert group defined a set of data elements essential for
research in resuscitation from out-of-hospital cardiac arrest.
The recommendations have been updated periodically to reflect
current evidence. They have enabled researchers to compare
studies effectively using meta-analyses. Subsequently, stan-
dardized data reporting was adopted in a number of related
areas, such as in-hospital resuscitation (Cummins et al., 1997),
pediatric resuscitation (Zaritsky et al., 1995), and laboratory
CPR research (Idris et al., 1996). Checklists have been intro-
duced in other fields of research, including PRISMA for sys-
tematic reviews and meta-analyses (Liberati et al., 2009; Moher
et al., 2009), STROBE for observational studies in epidemi-
ology (von Elm et al., 2014), CONSORT for randomized
controlled trials (Altman, 1996; Moher et al., 2010), SPIRIT for
standard protocol items for clinical trials (Chan et al., 2013),
and CARE for case reports (Rison et al., 2013). The goal of
these guidelines has been to render data reporting and research
more consistent and comparable.
A group of experts in the field of clinical HA research, the
STAR Core Group, established the ‘‘Strengthening Altitude
Research’’ (STAR) project. As in the process used to develop
the Utstein Style, the STAR project involved a large group of
experts in clinical HA research, who produced consensus-
based guidelines for standardized data reporting. Because the
community of researchers in HA is small, spread all over the
world and rarely meets at conferences, face-to-face meetings
were not practical. The STAR Core Group therefore made
use of an internet-based Delphi process facilitated by a re-
search group at the EURAC Research Institute of Mountain
Emergency Medicine in Bolzano, Italy.
Materials and Methods
Delphi method
The Delphi method is a structured, deliberative process
that uses a series of rounds with a group of experts who
FIG. 1. STAR Delphi Expert selection and evolution.
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collaborate anonymously. It was developed and described by
Brown, Dalkey, and Helmer from the RAND Corporation in
the 1960s (Dalkey, 1963; Brown, 1968) with the goal of ob-
taining the most reliable consensus of opinion within a group of
experts. The Delphi method is a widely used technique to find
consensus from respondents within their domain of expertise
(Hsu Chia-Chien, 2007). In this process, experts are repeatedly
consulted either by interview or questionnaire to avoid direct
confrontation between the experts. This is to ensure that the
assessment of parameters is purely based on independent ra-
tional judgment. An administrative group is responsible for
preparing the questionnaires or conducting interviews, sum-
marizing the results anonymously, feeding the results back to
the experts, and starting another round until consensus is
achieved at a predefined threshold. The STAR core group used
an electronic implementation of the Delphi method. The ex-
perts anonymously rated the predefined parameters as being
either core or supplemental. The experts could also provide
comments and suggest additional parameters. An 80% con-
sensus was the threshold for a parameter to be accepted as core
parameter. All the other parameters were included in the list of
either supplemental or unnecessary (‘‘futile’’) parameters.
Selection of experts
Experts in HA medicine were identified as candidates for the
STAR Delphi process using citations from the reference book
‘‘High Altitude Medicine and Physiology’’ (West et al., 2012)
and by a PubMed search for authors with at least five original
articles in the field of HA medicine between January 2000 and
January 2016. The list of 101 potential experts was reviewed by
the Core Group. Researchers who were members of a research
group that was already represented in the list of candidates for
the Delphi group by at least one expert, candidates who were
not active in clinical research on acute HA illnesses, and can-
didates who were no longer active in the field were excluded. In
all, 51 experts were identified as candidates and invited by
email to participate in the STAR Delphi process (Fig. 1).
Selection of STAR parameters
Clinically relevant parameters from the HA medicine lit-
erature were first identified by the STAR Core Group. The
parameters were then grouped by categories and entered into
an Excel spreadsheet. For STAR Delphi Round 1, 162 pa-
rameters were identified and divided into 7 categories: setting/
context, individual factors, AMS, high-altitude cerebral
edema (HACE), high-altitude pulmonary edema (HAPE),
treatment, and definitions. The parameters were then graded
by the STAR Delphi experts as follows: ‘‘core,’’ ‘‘supple-
mental,’’ or ‘‘futile.’’ For inclusion as a core parameter, at
least 80% of the experts had to rate a parameter as ‘‘core.’’
The definition of a parameter as ‘‘core’’ meant that it should
be reported in every clinical HA research article. ‘‘Supple-
mental’’ meant that a parameter may be reported depending
on the research question. ‘‘Futile’’ parameters were defined
as being either outdated or unnecessary. ‘‘Futile’’ parameters
were eliminated in Round 1. In Round 2, all remaining pa-
rameters were classified as either ‘‘core’’ or ‘‘supplemental.’’
Results
Before Round 1, 51 experts were selected and invited to
participate in the STAR Delphi process. Of the 51 invited
experts, 42 experts agreed and 32 completed Round 1. For
Round 2, 21 experts returned ratings.
In Round 1, 32 of the 162 proposed parameters reached
consensus as core parameters. The Delphi experts not only
rated the predetermined parameters but also provided a large
number of comments on the existing parameters, mainly re-
lated to the section of drugs. Moreover, they suggested ad-
ditional parameters for consideration. The feedback of the
Table 1. STAR Core Parameters
Section Parameters
Section 1:
Setting
(n = 6)
[1.1] Study location
[1.2] Setting
[1.3] Altitude
[1.4] Starting point of the ascent
[1.5] Maximum altitude reached
[1.6] Mode of ascent (active or passive)
Section 2:
Individual
factors
(n = 10)
[2.1] Age
[2.2] Sex
[2.3] Preexisting altitude exposure
[2.4] High-altitude native
[2.5] Preexisting health conditions
[2.6] History of prior AMS
[2.7] History of prior HACE
[2.8] History of prior HAPE
[2.9] Preacclimatization
[2.10] Altitude of residence
Section 3: AMS
and HACE
(n = 11)
[3.1] Headache
[3.2] Gastrointestinal symptoms
[3.3] Fatigue/weakness
[3.4] Dizziness/lightheadedness
[3.5] Ataxia
[3.6] Change in mental status
[3.7] AVPU
[3.8] SpO2
[3.9] Time of fulfilling AMS definition—
this suggests time of onset, not
diagnosis
[3.10] Time of fulfilling HACE
definition—same, needs to be
consistent with text
[3.11] Lake Louise AMS Score 2017
Section 4:
HAPE
(n = 11)
[4.1] Weakness/decreased exercise
performance
[4.2] Dyspnea at rest
[4.3] Cough
[4.4] Tachypnea
[4.5] Orthopnea
[4.6] Pink frothy sputum
[4.7] Respiratory rate
[4.8] Heart rate
[4.9] SpO2
[4.10] Rales and wheezing
[4.11] Time of fulfilling HAPE
definition—as above
Section 5:
Therapy
(n = 4)
[5.1] List all drugs with generic names,
dosages, mode of administration,
dosage intervals, and indication
[5.2] Supplemental oxygen
[5.3] Hyperbaric bag
[5.4] Descent
AMS, acute mountain sickness; AVPU, responsiveness assess-
ment, see text; HACE, high-altitude cerebral edema; HAPE, high-
altitude pulmonary edema; SpO2, oxygen saturation as measured by
pulse oximetry.
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experts resulted in major changes for Round 2: the AMS and
HACE sections were combined. In the Therapy section, the
STAR Core Group decided to replace the list of drugs with
the sentence to list all drugs used (see Section 5: Therapy).
Newly proposed parameters were added to the list, and the list
of futile parameters was withdrawn. Therefore, in Round 2,
the Delphi experts rated the parameters remaining from
Round 1 and the additional parameters as ‘‘core’’ or ‘‘sup-
plemental.’’ In Round 2, eight more parameters reached the
threshold of ‡80% consensus and were added to the list of
core parameters. Two parameters received ratings between
70% and 80% and were added as core parameters under the
discretion of the STAR core group. Altogether, 42 core pa-
rameters (Table 1) and 47 supplemental parameters (Table 2)
were identified.
STAR Core Parameters (Table 1)
Section 1: Setting
[1.1] Study location. The geographic location of the re-
search such as Kilimanjaro, Tanzania, Khumbu of Nepal,
Capanna Margherita of Italy, or Barcroft Station at White
Mountain Research Center, California.
[1.2] Setting. The setting refers to the study environment,
such as trekking, expedition, or chamber (normobaric or hypo-
baric). Setting applies to case reports as well as to formal studies.
[1.3] Altitude or simulated altitude. Altitude range at
which the study was conducted (study starting or enrollment
point to the study end point) or the altitude of a care setting or
research facility. The altitudes of data collection or of the oc-
currence and management of clinical cases should be reported.
[1.4] Starting point of ascent or simulated altitude. The
altitude at which individuals started trekking, hiking, or
climbing (for both active and passive ascents).
[1.5] Maximum altitude reached. The altitude achieved at
a particular time or day, including a day-hike if the sleeping
altitude was lower than day-hike. Alternatively, provision of
a full ascent profile should be reported. In the profile, start and
end of the ascent, altitude reached every day, and sleeping
altitude should be reported.
[1.6] Mode of ascent (active or passive). The means of
gaining altitude either actively, for example, by walking or
trekking, or passively, such as by chamber, car, helicopter,
airplane, or riding animal, including horse, mule, or yak.
Section 2: Individual characteristics
[2.1] Age. The age (in years) of the individual at the start
of the study.
[2.2] Sex. Male or female.
[2.3] Preexisting altitude exposure. Previous exposure to
a defined altitude by an individual within a previously defined
time period. Altitude and duration of stay should be reported.
[2.4] HA native. A person who was born and raised at HA
(typically >2500–3000 m), usually with previous generations
also resident at HA.
[2.5] Preexisting health conditions. Preexisting health
conditions should be reported. Examples of preexisting
conditions are as follows: cardiovascular such as hyperten-
sion or previous myocardial infarction, pulmonary such as
asthma or chronic obstructive pulmonary disease, neurolog-
ical such as migraine or previous stroke, or other conditions
such as diabetes, sleep breathing disorders, inherited genetic
disorders, or previous solid organ transplantation.
Table 2. STAR Supplemental Parameters
Setting Latitude
GPS location
Ambient temperature during
measurement
Wind
Precipitation
Study date
Measured barometric pressure
Altitude at which one sleeps each night
Air pollution
Individual factors Occupation
Ethnicity
Nutrition (special diet, nutritional
supplements, caffeine, etc)
Fluid balance/hydration
Objective fitness measurement
Training (please define)
Regular smoker
Regular alcohol consumer
Minimal physical assessment (respiratory
rate, heart rate, blood pressure, and
blood oxygen saturation at rest)
Hypoxic ventilatory response
Illness during study period
Symptoms Difficulty sleeping
Drowsiness
Signs Peripheral edema
Central cyanosis
Chest tightness or congestion
Blood pressure
Body temperature
Scores Time of first recorded AMS symptom
Time of first recorded HACE symptom
Time of first recorded HAPE symptom
AMS-C of ESQ-III
Additional exams CRP and white cell count
End-tidal CO2
NIRS
Spirometry/oscillatory resistance
Hypoxic ventilatory response
Respiratory muscle strength
Neuropsychometrics
Imaging Pulmonary ultrasound
Echocardiography
Optic nerve sheath ultrasound
TCD
Chest X-ray
Cerebral CT scan
Thoracic CT scan
Cerebral MRI
Therapy CPAP
AMS-C, AMS-cerebral; CO2, carbon dioxide; CPAP, Continuous
Positive Airway Pressure; CRP, C-reactive protein; CT scan, Computed
Tomography Scan; ESQ-III, Environmental Symptom Questionnaire-
III; GPS, global positioning system; MRI, Magnetic Resonance Imaging;
NIRS, Near-Infrared Spectroscopy; TCD; Transcranial Doppler.
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[2.6] History of prior AMS. History of AMS during pre-
vious HA exposure. If available, report the altitude(s) at which
AMS was diagnosed and reported signs and symptoms.
[2.7] History of prior HACE. History of HACE during
previous HA exposure(s). If available, report the altitude(s) at
which HACE was diagnosed and reported signs and symptoms.
[2.8] History of prior HAPE. History of HAPE during
previous HA exposure(s). If available, report the altitude(s) at
which HAPE was diagnosed and reported signs and symp-
toms.
[2.9] Preacclimatization. The number of days spent above
3000 m in the previous 2 months, excluding the current
ascent.
[2.10] Altitude of residence. The altitude at which the
subject lives.
Section 3: AMS and HACE
[3.1] Headache. Headache with a recent gain of altitude
is considered an HA headache, unless otherwise specified. If
not an HA headache, the type (e.g., cluster, tension headache,
or migraine) should be specified.
[3.2] Gastrointestinal symptoms. Gastrointestinal symp-
toms should be reported according to the new Lake Louise
AMS Score 2017 (Table 3) (Roach et al., 2017).
[3.3] Fatigue/weakness. Symptoms of fatigue or weak-
ness during ascent should be reported according to the new
Lake Louise AMS Score 2017 (Table 3).
[3.4] Dizziness/lightheadedness. Symptoms of dizziness
or lightheadedness should be reported according to the new
Lake Louise AMS Score 2017 (Table 3).
[3.5] Ataxia (HACE). Unsteady gait or inability to walk in
straight line heel-to-toe (tandem gait).
[3.6] Change in mental status (HACE). Assessment of
cognitive and behavioral functioning of the individual (ori-
entation to person, place and date; somnolence/confusion/
coma).
[3.7] AVPU (HACE). Responsiveness assessment, based
on the descriptions as ‘‘A’’ for alert, ‘‘V’’ for responsive to
verbal stimulation, ‘‘P’’ for responsive to painful (or other
noxious) stimuli, and ‘‘U’’ for unresponsiveness.
[3.8] SpO2%. The blood oxygen saturation in percentage
measured by pulse oximeter in the periphery, for example,
finger or ear lobe.
[3.9] Time of AMS onset. The length of time from arrival
to onset of AMS after arriving at the HA location at which
AMS was diagnosed. The diagnosis of AMS should be es-
tablished by the New Lake Louise AMS Score (Table 3). The
duration from arrival to onset should be reported in hours or
days.
[3.10] Time of HACE onset. The length of time from
arrival to onset of HACE after arriving at the HA location at
which HACE was diagnosed. The diagnosis of HACE should
be established by the current Lake Louise Consensus criteria
(Table 4). The duration from arrival to onset should be re-
ported in hours or days.
[3.11] Lake Louise AMS Score 2017. For the new Lake
Louise AMS Score 2017 for the diagnosis of AMS (Table 3).
Table 3. Lake Louise Acute Mountain
Sickness Score 2017
Headache:
0 None at all
1 A mild headache
2 Moderate headache
3 Severe headache, incapacitating
Gastrointestinal symptoms:
0 Good appetite
1 Poor appetite or nausea
2 Moderate nausea or vomiting
3 Severe nausea and vomiting, incapacitating
Fatigue and/or weakness:
0 Not tired or weak
1 Mild fatigue/weakness
2 Moderate fatigue/weakness
3 Severe fatigue/weakness, incapacitating
Dizziness/lightheadedness:
0 No dizziness/lightheadedness
1 Mild dizziness/lightheadedness
2 Moderate dizziness/lightheadedness
3 Severe dizziness/lightheadedness, incapacitating
Lake Louise AMS functional score
Overall, if you had AMS symptoms, how did they affect
your activities?
0 Not at all
1 Symptoms present, but did not force any change in
activity or itinerary
2 My symptoms forced me to stop the ascent or to go
down on my own power
3 Had to be evacuated to a lower altitude
Roach et al. (2017).
Table 4. Lake Louise Consensus Definitions
of High-Altitude Cerebral Edema
and High-Altitude Pulmonary Edema
HACE
In the setting of a recent gain in altitude, the presence of
change in mental status or ataxia in a person with AMS,
or the presence of both mental status change and ataxia in
a person without AMS.
HAPE
In the setting of a recent gain in altitude, the presence of
the following:
Symptoms: at least two of the following: dyspnea at rest,
cough, weakness or decreased exercise performance, and
chest tightness or congestion.
AND
Signs: at least two of the following: rales or wheezing in
at least one lung field, central cyanosis, tachypnea, and
tachycardia.
Adapted from Lake Louise Consensus Definitions of Altitude-
Related Health Problems (Roach et al., 1991).
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The score is intended for use by investigators studying AMS
and is defined as sum of the four symptoms. AMS definition
is positive with a headache score of at least one point and a
total score of at least three points (Roach et al., 2017).
Section 4: HAPE
[4.1] Weakness or decreased exercise performance. Feel-
ing weak or having the perception of decreased exercise
performance.
[4.2] Dyspnea at rest. Shortness of breath at rest.
[4.3] Cough. Cough can be productive or dry (nonpro-
ductive).
[4.4] Tachypnea. Abnormally rapid breathing. A faster
than normal rate of breathing at rest. The threshold for ta-
chypnea varies depending on sex, fitness, preexisting condi-
tions, and altitude.
[4.5] Orthopnea. Shortness of breath when lying down.
[4.6] Pink frothy sputum. Sputum produced during cough
that is aerated (frothy) and pink colored (suggestive of
blood).
[4.7] Respiratory rate. Number of breaths per minute
counted by an observer or measured by an equipment.
[4.8] Heart rate. Number of beats per minute recorded by
an observer or by a device.
[4.9] SpO2%. Hemoglobin oxygen saturation measured
peripherally (usually finger or ear lobe) by pulse oximeter.
SpO2 is reported as the percentage of hemoglobin that is
bound to oxygen. Oxygen saturation by arterial blood gas
(SaO2) may be reported, but is not necessary in most cases.
[4.10] Crackles (rales) or wheezing in at least one lung
field. Pathological breath sounds during chest auscultation,
described as crackles (rales), which are coarse crackling
sounds, or wheezes, which are high-pitched whistling sounds.
[4.11] Time of HAPE onset. The length of time from
arrival to onset of HAPE after arriving at the HA location at
which HAPE was diagnosed. The diagnosis of HAPE should
be established by the Lake Louise Consensus criteria (Ta-
ble 4). The duration from arrival to onset should be reported
in hours or days.
Section 5: Therapy
[5.1] List of all drugs used. Drugs or medication of any
type used during HA sojourn for the prevention or treatment
of altitude-related health problems or for preexisting condi-
tions, delivered orally or parenterally. For each drug, report
the generic name, dosage, mode of administration, dosage
intervals, and indication.
[5.2] Supplemental oxygen. The flow of supplemental
oxygen in L/min, from bottled oxygen or from a concentrator,
provided to a patient through mask or cannula. For intubated
patients, report the fraction of inspired oxygen (FiO2).
[5.3] Portable hyperbaric chamber (simulated descent). An
air-impermeable bag that completely envelops a patient and is
inflated to a significant pressure above ambient atmospheric
pressure. Specific models include the following: Gamow
bag, Certec bag, and PAC (Portable Altitude Chamber).
Indicate duration(s) in the chamber and pressure of inflation or
equivalent altitude maintained during treatment.
[5.4] Descent (actual descent). Lowering the altitude by
physically moving the individuals by any means, such as
walking or climbing, riding on an animal, by vehicle, or air,
or by being carried by porter from higher to lower altitude.
This should be quantified by the difference in altitude and the
amount of time spent descending.
Discussion
A core group of experts in HA research convened an in-
ternational group of 42 colleagues with appropriate scientific
credentials to participate in a Delphi process to develop
consensus guidelines for data reporting in clinical HA med-
icine research. From a preliminary list of 98 parameters that
had been defined by the STAR core group, the experts
reached ‡80% consensus on each of 42 core parameters for
clinical research in HA medicine. These parameters should
be mandatory for research proposals and reports of HA. They
also reached consensus on a second open-ended list of 47
supplemental parameters (Table 2). The supplementary pa-
rameters depend on the specific research question. Reporting
of supplemental parameters is not mandatory for every re-
search article.
Reproducibility of study results is one of the most con-
cerning issues in natural and medical sciences. Since the
1990s, guidelines have been developed for reporting results
in many fields of medical research in an attempt to improve
reproducibility of research. Guidelines include the Utstein
Style (Cummins et al., 1991, 1997; Zaritsky et al., 1995; Idris
et al., 1996), PRISMA (Liberati et al., 2009; Moher, et al.,
2009), STROBE (von Elm et al., 2014), CONSORT (Altman,
1996; Moher et al., 2010), SPIRIT (Chan et al., 2013), and
CARE (Rison et al., 2013). Developing guidelines for data
reporting in clinical HA medicine is important because the
number of studies is rapidly increasing. There are many ad-
vantages to better uniformity of clinical HA research studies.
Sample sizes are often small in prospective HA studies.
Studies are heterogeneous, especially in relation to study
setting, study populations, and definitions of altitude ill-
nesses. Research at the Capanna Regina Margherita, one of
the most frequently used HA field sites in the Alps, is based
on an ascent from 490 to 4559 m in around 24–36 hours
(Hochstrasser et al., 1986; Ferrazzini et al., 1987; Goerre
et al., 1995; Scherrer et al., 1996; Agostoni et al., 2013). The
‘‘classic’’ ascent from Lukla (2850 m) to Everest Base Camp
(5380 m) takes 7–10 days. These settings substantially differ
in altitude and ascent rate. Confounding factors such as the
means of ascent, varying by speed of ascent and level of
exercise, and environmental factors, such as exposure to
temperature extremes, wind, humidity, and precipitation, are
poorly reported. Similar considerations apply to different
study populations, such as subjects from different ethnicities,
lowlanders versus highlanders, and subjects with different
degrees of acclimatization.
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Use of the 42 core and 47 supplemental parameters can
facilitate comparisons among studies and can provide a basis
to perform reliable meta-analyses, strengthening the findings
and providing robust evidence for prevention, diagnosis, and
treatment of altitude illnesses. This open-ended list can shed
light on new developments in clinical HA research and needs
regular updates. We hope that use of the STAR guidelines
will improve data reporting in HA research, improve repro-
ducibility, and facilitate comparison among studies.
Limitations
In addition to the 51 international experts identified by the
STAR group, there may have been many other equally
qualified experts. We do not know how the results would
have differed if additional experts had been identified. We
also do not know how results would have differed if the 19
identified experts who did not collaborate had participated in
one or more rounds or if the 11 experts who dropped out after
Round 1 had participated in both rounds. We do not have any
information about reasons for nonparticipation at any of the
stages.
STAR Delphi Round 1 revealed potential flaws in the list
of parameters. There was considerable discussion regarding
the definitions of AMS, HACE, and HAPE. Some experts
questioned the clinical significance and consistency of some
of the diagnostic criteria of AMS, particularly the category of
sleep disturbance. At the time of the Delphi process, the
STAR core group based the STAR criteria on the 1991 Lake
Louise Consensus definitions of HA illnesses. Coin-
cidentally, the Lake Louise AMS Score was under revision
when the STAR article was submitted. For the revised STAR
article, the STAR Core Group integrated the new Lake
Louise AMS Score 2017 (Roach et al., 2017) (Table 3).
Conclusions
The STAR consensus guidelines, developed by a Delphi
process, describe 42 core parameters that should be reported
in clinical research articles on HA-related health problems
and 47 supplemental parameters that should be reported,
depending on the research question. We anticipate regular
updates of the guidelines as new evidence is published in the
dynamic field of clinical HA research.
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